Study guide

5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders

ASCP Hematology Technologist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Hematopoiesis & Cellular Physiology

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis

2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias

2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias

3 Chapter 3: Hemolytic Anemias & Erythrocytosis

3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification

4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation

4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment

5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms

5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation

7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays

8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics

8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis

9 Chapter 9: Laboratory Operations, Quality Assessment & Safety

9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges

5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders

Key Takeaways Explain This Topic AI

Diffuse large B-cell lymphoma is the most common non-Hodgkin lymphoma: sheets of large CD19+, CD20+, CD22+, CD79a+ B cells; concurrent MYC with BCL2 or BCL6 rearrangement reclassifies it as high-grade 'double-hit' disease with a worse prognosis.

Burkitt lymphoma shows 'starry sky' histology with tingible-body macrophages, deeply basophilic vacuolated cytoplasm on smear, t(8;14)(q24;q32) MYC::IGH, CD10+, BCL6+, BCL2 NEGATIVE, and a Ki-67 near 100%.

Classical Hodgkin lymphoma is defined by binucleated 'owl-eye' Reed-Sternberg cells in a reactive inflammatory background; they are CD30+, CD15+, PAX5 dim, and CD45 NEGATIVE, which separates them from all non-Hodgkin lymphomas.

Sezary syndrome is the leukemic phase of cutaneous T-cell lymphoma: erythroderma, lymphadenopathy, and circulating cerebriform Sezary cells that are CD3+, CD4+, and characteristically CD7 negative.

Adult T-cell leukemia/lymphoma follows HTLV-1 infection and presents with hypercalcemia, lytic bone lesions, and circulating multilobed 'flower cells' that are CD3+, CD4+, and CD25 bright.

Last updated: August 2026

Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders

This section covers high-grade aggressive lymphomas, plasma cell dyscrasias, and post-thymic mature T-cell/NK-cell neoplasms. Rapid laboratory identification, flow cytometric immunophenotyping, and cytogenetic characterization are essential for establishing prompt diagnoses and directing emergency therapeutic interventions.

  • 1. Aggressive Mature B-Cell Lymphomas AGGRESSIVE B-CELL LYMPHOMAS
  • │
  • ┌────────────────────────────────┴────────────────────────────────┐
  • ▼ ▼
  • [ DIFFUSE LARGE B-CELL LYMPHOMA ] [ BURKITT LYMPHOMA ]
  • Most Common NHL (30-40%) • Fast Doubling Time (~24 hrs)
  • Large Cells (≥2× Lymphocyte) • EBV Association
  • CD19+, CD20+, CD79a+, PAX5+ • "Starry Sky" Histology
  • Double-Hit: MYC + BCL2/BCL6 • Basophilic Vacuolated Blasts
  • t(8;14) MYC::IGH Translocation
  • Ki-67 Proliferation Index ~100%
  • A. Diffuse Large B-Cell Lymphoma (DLBCL)

Epidemiology : The most common subtype of non-Hodgkin lymphoma worldwide, accounting for 30% to 40% of newly diagnosed adult lymphomas. Presents as a rapidly expanding nodal or extranodal mass (e.g., gastrointestinal tract, bone, brain, Waldeyer ring).

Morphology : Complete effacement of normal tissue architecture by diffuse sheets of large lymphoid cells. Neoplastic cells have diameters ≥ 2 × \ge 2\times ≥ 2 × the size of a normal resting lymphocyte (or larger than a histiocyte nucleus), with vesicular chromatin, 1 to 3 prominent nucleoli, and moderate amounts of basophilic cytoplasm.

Immunophenotype : Broad pan-B-cell marker expression: CD19+ , CD20+ , CD22+ , CD79a+ , and PAX5+ .

Molecular Subtypes & Double-Hit Lymphoma : Gene expression profiling classifies DLBCL into Germinal Center B-cell-like (GCB) and Activated B-cell-like (ABC) subtypes (the Hans immunohistochemical algorithm uses CD10, BCL6, and MUM1 as surrogates). High-Grade B-cell Lymphoma with Double-Hit or Triple-Hit Genetics harbors concurrent chromosomal translocations involving M Y C MYC M Y C (8q24) and B C L 2 BCL2 BC L 2 (18q21) and/or B C L 6 BCL6 BC L 6 (3q27) , conferring extreme chemoresistance and poor prognosis.

B. Burkitt Lymphoma (BL)

Epidemiology & Variants : One of the fastest-growing human malignancies, with a potential tumor doubling time of approximately 24 hours. Occurs in three clinical settings: Endemic (equatorial Africa; pediatric jaw/facial bone tumors; > 95 % >95\% > 95% associated with Epstein-Barr Virus [EBV]), Sporadic (worldwide; children and young adults; abdominal/ileocecal mass), and Immunodeficiency-Associated (HIV infection).

Cytogenetics : Hallmark reciprocal translocation t ( 8 ; 14 ) ( q 24 ; q 32 ) \text{t}(8;14)(\text{q}24;\text{q}32) t ( 8 ; 14 ) ( q 24 ; q 32 ) in > 85 % >85\% > 85% of cases, translocating the M Y C MYC M Y C proto-oncogene on 8q24 to the I G H IGH I G H enhancer locus on 14q32. Variant translocations include t ( 2 ; 8 ) ( p 12 ; q 24 ) \text{t}(2;8)(\text{p}12;\text{q}24) t ( 2 ; 8 ) ( p 12 ; q 24 ) [ I G K : : M Y C IGK::MYC I G K :: M Y C ] and t ( 8 ; 22 ) ( q 24 ; q 11.2 ) \text{t}(8;22)(\text{q}24;\text{q}11.2) t ( 8 ; 22 ) ( q 24 ; q 11.2 ) [ M Y C : : I G L MYC::IGL M Y C :: I G L ]. Constitutive MYC oncoprotein overexpression drives continuous transcription of cell-cycle genes.

Histology & Cytology :

"Starry Sky" Histology : Low-power tissue microscopy reveals a dark background ("sky") of monomorphic basophilic neoplastic B-cells undergoing high rates of apoptosis, interspersed with numerous pale tingible-body macrophages ("stars") containing ingested apoptotic debris and clear lipid vacuoles.

Smear / Touch Prep : Monomorphic intermediate-sized lymphocytes with round nuclei, coarsely clumped chromatin, multiple prominent basophilic nucleoli, and deeply royal-blue cytoplasm filled with numerous sharply defined, lipid-containing vacuoles (which stain positively with Oil Red O).

Immunophenotype & Ki-67 : CD19+ , CD20+ (bright) , CD10+ , BCL6+ , surface IgM+ with light chain restriction, and BCL2 NEGATIVE (essential for distinguishing from double-hit DLBCL). The Ki-67 (MIB-1) proliferation fraction is virtually 100% .

Tumor Lysis Syndrome (TLS) : Massive cellular turnover and rapid response to cytotoxic chemotherapy release intracellular contents, causing life-threatening hyperuricemia, hyperkalemia, hyperphosphatemia, and secondary hypocalcemia with acute uric acid nephropathy.

2. Classical Hodgkin Lymphoma (cHL)

Classical Hodgkin Lymphoma is a unique mature B-cell-derived neoplasm characterized by a tiny population ( < 1 % <1\% < 1% ) of clonal malignant giant cells surrounded by an overwhelming background of non-neoplastic, reactive inflammatory cells. CLASSICAL HODGKIN LYMPHOMA ARCHITECTURE

  • ┌─────────────────────────────────────────────────────────────────────────┐
  • │ REACTIVE INFLAMMATORY BACKGROUND │
  • │ (Polyclonal CD4+ T-Cells, Eosinophils, Plasma Cells, Histiocytes) │
  • │ │
  • │ ┌──────────────────────────────────────────────────┐ │
  • │ │ MALIGNANT REED-STERNBERG (RS) CELLS │ │
  • │ │ • Large Binucleated / Multinucleated Giant Cells │ │
  • │ │ • Prominent Eosinophilic "Owl-Eye" Nucleoli │ │
  • │ │ • Perinuclear Clear Halos │ │
  • │ │ • Immunophenotype: CD30+, CD15+, PAX5+ (Dim) │ │
  • │ │ CD45- (LCA Negative), CD20-, CD3- │ │
  • │ └──────────────────────────────────────────────────┘ │
  • └─────────────────────────────────────────────────────────────────────────┘
  • Epidemiology & Clinical Features

Bimodal Age Distribution : Peaks in young adults aged 15 to 35 years, with a second peak in adults > 55 >55 > 55 years.

Presentation : Painless, rubbery cervical, supraclavicular, or mediastinal lymphadenopathy. Patients frequently experience B-symptoms (unexplained fever > 38 ∘ C >38^\circ\text{C} > 3 8 ∘ C , drenching night sweats, > 10 % >10\% > 10% weight loss over 6 months), generalized pruritus, and pain in diseased lymph nodes following alcohol ingestion.

Diagnostic Cytology

Reed-Sternberg (RS) Cell : The diagnostic hallmark. A giant cell ( 20 – > 50 μ m 20\text{--}>50\ \mu\text{m} 20 – > 50 μ m ) containing two or more mirror-image nuclear lobes ("owl-eye" appearance) or multinucleated configurations. Each lobe contains an enormous, inclusion-like, purple-red eosinophilic nucleolus surrounded by a clear perinuclear halo.

Mononuclear Hodgkin Cell : Single-nucleus variants with identical prominent eosinophilic nucleoli.

Lacunar Cell : Specialized RS variant seen in the Nodular Sclerosis subtype; the cytoplasm retracts during formalin fixation, leaving the nucleus sitting in an empty space or "lacuna".

Reactive Microenvironment : Malignant RS cells secrete cytokines (IL-5, IL-13, TGF- β \beta β , CCL28) that recruit small non-clonal CD4+ T-lymphocytes (which form rosettes around RS cells), eosinophils, plasma cells, and histiocytes .

Subtypes of Classical Hodgkin Lymphoma

Nodular Sclerosis (NS-cHL) : Most common subtype (~70%); young adults, female predominance; mediastinal mass; dense broad collagen bands dividing lymph node into nodules; lacunar cells.

Mixed Cellularity (MC-cHL) : ~20–25%; older patients, male predominance; rich in eosinophils, plasma cells, and histiocytes; high association with EBV (~75%) .

Lymphocyte-Rich (LR-cHL) : ~5%; background dominated by mature small lymphocytes with classic RS cells; favorable prognosis.

Lymphocyte-Depleted (LD-cHL) : < 1 % <1\% < 1% ; abundant pleomorphic RS cells with few background lymphocytes; aggressive, elderly/HIV+ patients. (Note: Nodular Lymphocyte Predominant Hodgkin Lymphoma [NLPHL] is a separate, non-classical entity characterized by "popcorn cells" [LP cells] expressing CD20+, CD45+, CD30-, CD15-).

Diagnostic Immunophenotype of Classical RS Cells

CD30+ (Ki-1) : Strong membranous and Golgi-zone dot-like staining in virtually 100% of cases.

CD15+ (Leu-M1) : Positive in 75 – 85 % 75\text{--}85\% 75 – 85% of cases.

PAX5+ (Dim / Weak) : Weak B-cell transcription factor positivity (proves B-cell origin despite loss of immunoglobulin synthesis).

CD45 (LCA) NEGATIVE : Malignant RS cells lose leukocyte common antigen.

CD20 Negative (or weak/focal variable) ; CD3 NEGATIVE .

3. Mature T-Cell & NK-Cell Disorders

Mature T-cell neoplasms are uncommon ( < 10 % <10\% < 10% of all non-Hodgkin lymphomas) and arise from post-thymic mature T-lymphocytes. MATURE T-CELL NEOPLASMS

  • │
  • ┌──────────────────────────────┴──────────────────────────────┐
  • ▼ ▼
  • [ SÉZARY SYNDROME / MF ] [ ADULT T-CELL LEUKEMIA/LYMPHOMA ]
  • Cutaneous T-Cell Lymphoma • HTLV-1 Retrovirus Association
  • Triad: Erythroderma + Lymphadenopathy • Japan, Caribbean, South America
  • + Circulating Sézary Cells (≥1.0 × 10^9/L) • Profound Hypercalcemia & Bone Lesions
  • Cerebriform / Brain-like Folded Nuclei • "Flower Cells" / Clover-Leaf Nuclei
  • CD3+, CD4+, CD7 Negative, CD26 Negative • CD3+, CD4+, CD25+ (Bright)
  • A. Mycosis Fungoides (MF) & Sézary Syndrome (SS)

Mycosis Fungoides : The most common cutaneous T-cell lymphoma (CTCL), characterized by skin-homing CD4+ memory helper T-cells producing erythematous patches, plaques, and cutaneous tumors with epidermal infiltration ( Pautrier microabscesses ).

Sézary Syndrome Triad : The leukemic, aggressive variant of CTCL, clinically defined by the triad of:

Erythroderma : Diffuse, intensely pruritic, exfoliative redness covering > 80 % >80\% > 80% of the body surface area.

Generalized Lymphadenopathy .

Circulating Sézary Cells : Clonal circulating T-cells ≥ 1.0 × 10 9 / L \ge 1.0 \times 10^9/\text{L} ≥ 1.0 × 1 0 9 / L ( 1 , 000 / μ L 1,000/\mu\text{L} 1 , 000/ μ L ) or ≥ 10 % \ge 10\% ≥ 10% of lymphocytes.

Sézary Cell Morphology : Medium-to-large mature lymphocytes with highly distinctive cerebriform / hyperconvoluted / brain-like grooved nuclei with condensed chromatin and scant cytoplasm.

Immunophenotype : Mature T-helper profile: CD2+ , CD3+ , CD4+ , CD5+ , with characteristic loss of CD7 (CD7 NEGATIVE) and loss of CD26 (CD26 NEGATIVE) ; CD8 negative.

B. Adult T-Cell Leukemia / Lymphoma (ATLL)

Etiology & Epidemiology : Caused by infection with the Human T-Cell Lymphotropic Virus type 1 (HTLV-1) retrovirus. Endemic in Southwestern Japan, the Caribbean basin, parts of Central/South America, and equatorial Africa.

Clinical Features : Acute ATLL presents aggressively with marked leukocytosis, profound hypercalcemia (due to tumor secretion of PTHrP), lytic bone lesions, hepatosplenomegaly, skin lesions, and generalized lymphadenopathy.

Pathognomonic Cytology : "Flower Cells" (Clover-Leaf Cells) —circulating atypical lymphocytes with deeply indented, polylobated nuclear contours resembling the petals of a flower, with condensed chromatin and basophilic cytoplasm.

Immunophenotype : CD3+ , CD4+ , CD25+ (IL-2 receptor α \alpha α -chain, uniformly bright positive) , CD7 negative, CD8 negative.

Loading diagram... Cytologic and Immunophenotypic Triage of Aggressive Lymphomas and Mature T-Cell Neoplasms